Carisma Therapeutics, Inc. is a clinical-stage biopharmaceutical company at the forefront of immuno-oncology, dedicated to revolutionizing cancer treatment through the development of engineered macrophage-based therapeutics. Their proprietary platform focuses on harnessing the power of macrophages, a type of white blood cell, by engineering them with chimeric antigen receptors (CARs) to target and destroy cancer cells. This innovative CAR-Macrophage (CAR-M) approach offers a differentiated mechanism of action compared to other cell therapies, potentially overcoming limitations of current treatments and addressing a broader range of solid tumors. Carisma is advancing a pipeline of programs, with its lead candidate, CT-0508, an anti-HER2 CAR-M, in clinical trials for patients with HER2-overexpressing solid tumors. The company is committed to scientific excellence and translating groundbreaking research into life-changing medicines for patients with unmet medical needs.
Serves as the central hub for all research and development, clinical operations, and corporate functions. This includes laboratory research, process development, clinical trial management, and administrative activities.
Located within the uCity Square innovation district, providing access to a vibrant ecosystem of life science companies, research institutions, and talent. The facility includes state-of-the-art laboratory and office spaces.
Characterized by a dynamic, innovative, and collaborative environment. Employees are typically mission-driven, focused on scientific rigor and a shared goal to develop transformative therapies for patients with serious diseases.
The Philadelphia headquarters is pivotal for Carisma's operations, as it is the primary site for the discovery, development, and advancement of its novel CAR-Macrophage platform technology and clinical programs.
While Carisma Therapeutics' primary operations and headquarters are based in the United States, its mission to develop novel cancer therapies has global implications. The company's research addresses diseases affecting patients worldwide, and its clinical trials may involve international sites. Future commercialization efforts for successful therapies would likely involve a global strategy to reach patients in need across different regions.
3675 Market Street, Suite 200
Philadelphia
PA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Carisma Therapeutics' leadership includes:
Carisma Therapeutics has been backed by several prominent investors over the years, including:
In January 2024, Carisma Therapeutics announced significant leadership transitions to align with its strategic pipeline prioritization. This included the appointment of a new CEO, CFO, CTO, and Chief Strategy Officer, a transition for the co-founder to CSO, and the departure of the former CFO.
Discover the tools Carisma Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Carisma Therapeutics, Inc. commonly utilizes the email format [first_initial][last]@carismatx.com (e.g., jsmith@carismatx.com). This pattern is frequently observed for company communications.
[first_initial][last]@carismatx.com
Format
skelly@carismatx.com
Example
85%
Success rate
GlobeNewswire • May 14, 2024
Carisma Therapeutics announced its Q1 2024 financial results, providing updates on its clinical programs, including the CT-0508 HER2-targeted CAR-M and CT-0525 anti-PSMA CAR-M therapies. The company discussed its development strategy and financial position....more
GlobeNewswire • March 7, 2024
The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to Carisma Therapeutics' lead investigational candidate, CT-0508, an anti-HER2 CAR-Macrophage, for the treatment of gastric cancer. This designation aims to facilitate the development of therapies for rare conditions....more
GlobeNewswire • January 9, 2024
Carisma Therapeutics announced significant leadership changes, with Steven Kelly becoming CEO and Michael Klichinsky transitioning to CSO. The company also outlined a pipeline prioritization to focus on its core engineered macrophage programs, CT-0508 and CT-0525....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Carisma Therapeutics, are just a search away.